[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"IRCCS Centro Neurolesi Bonino Pulejo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":398},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,48,84,108,129,149,170,190,216,245,273,298,323,346,374],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100622583","neurorehabilitation-in-patients-with-disorders-of-consciousness-multidimensional-ambispective-study-on-the-impact-of-single-and-combined-approaches-100622583",false,"NCT07385508","Neurorehabilitation in Patients With Disorders of Consciousness: Multidimensional Ambispective Study on the Impact of Single and Combined Approaches","Inclusion Criteria:\n\n* Diagnosis of VS\u002FMCS following ABI, according to clinical and neuroradiological findings.\n* Age between 18 and 90 years.\n* Adequate pulmonary gas exchange function (PaO₂ \u002F FiO₂ ratio ≥ 250).\n* Stable haemodynamic profile (absence of significant arterial variations in mean arterial pressure and\u002For heart rate).\n\nExclusion Criteria:\n\n* Diagnosis of DOC due to non-structural aetiopathogenesis.\n* Having previously undergone multiple rehabilitation cycles\n* Being affected by deafness and\u002For blindness\n* Having unstable intracranial pressure values\n* Having cerebral perfusion values below 60 mmHg\n* Having other concomitant medical conditions that could interfere with the rehabilitation","ALL","18 Years","90 Years",{"count":19,"type":20},140,"ESTIMATED","36 Months","OBSERVATIONAL","Disorders of consciousness (DOC), such as the vegetative state\u002Funresponsive wakefulness syndrome (VS\u002FUWS) and the minimally conscious state (MCS), represent severe clinical conditions arising from acquired brain injury (ABI), exerting a profound impact on patients, caregivers, and healthcare systems. The clinical heterogeneity, diagnostic challenges, and paucity of robust evidence on the comparative efficacy of rehabilitation interventions underscore the need for a deeper understanding of the underlying neurophysiological, cognitive, and biological mechanisms involved in consciousness recovery. This monocentric ambispective observational study aims to investigate the effects of advanced neurorehabilitation treatments-including multimodal sensory stimulation, non-invasive neuromodulation via transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS), and the use of augmentative and alternative communication (AAC) devices with eye-tracking-on various facets of residual consciousness in patients diagnosed with DOC admitted to the Neurorehabilitation Unit of the IRCCS Centro Neurolesi \"Bonino Pulejo\" in Messina.\n\nThe study design encompasses the collection of clinical and rehabilitation data from hospitalized patients undergoing treatment, both retrospectively and prospectively. Specifically, data from patients admitted and treated in the 36 months preceding study initiation, as well as those admitted and treated in the subsequent 36 months, will be included. Upon data collection, participants will be classified a posteriori as \"responders\" or \"non-responders\" based on whether they meet at least one of the following criteria: (I) an increase of ≥3 points on the Coma Recovery Scale-Revised (CRS-R) from baseline or a clinically relevant state transition (e.g., VS\u002FUWS → MCS; MCS → emergence from MCS \\[EMCS\\]); (II) an increase of ≥10 points on the Functional Independence Measure (FIM) or ≥0.5 standard deviations (SD) from baseline; (III) an increase of ≥10 points on the Barthel Index or ≥0.5 SD from baseline.\n\nThe primary objective is to estimate the proportion of responders and non-responders at the end of training or hospitalization. Secondary objectives include identifying variables predictive of treatment response at the end of intervention (training type\u002Fmodality, aetiology, demographic factors, comorbidities), quantifying the dose-response gradient (number of sessions\u002Fsession duration versus response probability), and assessing changes in neurophysiological, physiological, and biological parameters collected during hospitalization (neuroimaging examinations, neurofilament light chain \\[NfL\\] assays, EEG\u002Fevent-related potentials \\[ERP\\], skin conductance response, heart rate frequency and variability, and oculomotor activity).\n\nData will be analysed using descriptive statistics appropriate to variable distributions. The primary endpoint, defined as the proportion of responders at the end of training\u002Fhospitalization, will be evaluated using logistic regression models in an as-treated approach, reporting odds ratios and marginal estimates (risk ratios and absolute risk differences) with 95% confidence intervals (CI). Confounding will be addressed through multivariable adjustment and propensity score-based methods (inverse probability of treatment weighting \\[IPTW\\]\u002Foverlap weighting). Continuous secondary outcomes will be analysed with linear models or linear mixed-effects models for repeated measures. Dose-response relationships will be explored, alongside sensitivity and subgroup analyses. All analyses will be performed using R software (version 4.4.2), employing two-sided tests with a significance level of α=0.05. The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.",[25],"Disorder of Consciousness",[27,28,29,30,31,32,33,34],"Vegetative state","Minimally conscious state","Neurorehabilitation","Eye-tracking","Neurofilaments","tDCS","multimodal sensory stimulation","Skin conductance response","RECRUITING","2026-05-25",{"date":38,"type":39},"2026-05-27","ACTUAL",{"date":41,"type":39},"2026-01-16",{"date":43,"type":20},"2029-01-16",{"name":45,"class":46},"IRCCS Centro Neurolesi Bonino Pulejo","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":47},"100577087","effectiveness-of-televr-app-in-cognitive-decline-and-mci-patients-100577087","NCT06793735","Effectiveness of TeleVR App in Cognitive Decline and MCI Patients","Effectiveness of Telerehabilitation Plus Virtual Reality App in Patients With Subjective Cognitive Decline, and Mild Cognitive Impairment","TeleVR24","Inclusion Criteria:\n\n* Subjects diagnosed with MCI (AD and PD) according to the criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA, Albert et al., 2011)\n* Subjects diagnosed with SCD according to diagnostic criteria proposed in research settings (Molinuevo et al., 2017)\n* All enrolled subjects must be aged between 40 and 80 years and have at least 5 years of education\n\nExclusion Criteria:\n\n* Presence of psychiatric disorders (major depression, psychosis, anxiety disorders)\n* Presence of severe dementia\n* History of cerebral ischemia\n* Contraindications to brain MRI: pregnant women, pacemakers, non-latest-generation metal joint prostheses, electrodes, neurostimulators, or prostheses that may interfere with magnetic fields, unless there is a written statement of suitability from the specialist who performed the intervention","40 Years","80 Years",{"count":59,"type":20},480,"INTERVENTIONAL",[62],"NA","The goal of this clinical trial is to evaluate the effectiveness of a telerehabilitation program combined with a virtual reality (VR) app in improving cognitive performance and social skills in patients with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).\n\nThe main questions it aims to answer are:\n\nCan a VR telerehabilitation program improve cognitive functions and social skills in patients with SCD and MCI? Are there measurable changes in brain activity, eye movements, and gait patterns after the intervention? Researchers will compare telerehabilitation with a VR group (Experimental Group - EG) to a traditional paper-based cognitive rehabilitation group (Active Control Group - aCG) to determine which approach is more effective.\n\nParticipants will:\n\nUndergo an initial assessment, including neurological exams, neuropsychological tests, brain MRI, EEG, eye movement analysis, and gait evaluation.\n\nParticipate in a 6-week intervention program:\n\nEG: Use VR apps on smartphones\u002Ftablets at home, guided remotely by a therapist. aCG: Perform traditional cognitive exercises using paper-based tasks. Complete follow-up assessments immediately after the intervention and again after three months.\n\nThis study will help determine whether telerehabilitation with VR can provide measurable cognitive and social benefits, contributing to improved care strategies for individuals at risk of dementia.",[65,66,67,68,69],"Cognitive Dysfunction","Subjective Health","Mild Cognitive Impairment","Alzheimer Disease","Parkinson Disease",[71,72,73,74,75],"Telerehabilitation","Virtual Reality (VR)","Mild Cognitive Impairment (MCI)","Subjective Cognitive Decline (SCD)","Cognitive Rehabilitation","2026-04-02",{"date":78,"type":39},"2026-04-03",{"date":80,"type":39},"2025-01-08",{"date":82,"type":20},"2026-12-31",{"name":45,"class":46},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":15,"minAge":16,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":60,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":47},"100535411","study-of-the-dynamics-of-verbal-and-non-verbal-interaction-in-healthy-subjects-through-the-recording-of-body-movements-and-non-invasive-neurophysiological-techniques-100535411","NCT06251479","Study of the Dynamics of Verbal and Non-verbal Interaction in Healthy Subjects, Through the Recording of Body Movements and Non-invasive Neurophysiological Techniques","OMNIBUS2023","Inclusion Criteria:\n\n* Age range between 18 and 55 years\n* written informed consent\n* healthy subjects\n\nExclusion Criteria:\n\n* epilepsy or at risk of epileptic seizures,\n* cardiac pacemaker wearers,\n* presence of an implanted infusion pump,\n* metal plaques in the skull or metal objects in the eye and skull taking neuroleptic drugs or tricyclic antidepressants,\n* migraine or at risk of developing this disease.",true,"55 Years",{"count":94,"type":20},200,[62],"Based on study literature, the investigators can say that our study aims to give an explanation not only from a behavioral point of view but also with respect to what are the neuronal mechanisms underlying our ability to perceive and analyze our own and others' actions. This is essential to fully understand the complexity of our social behaviors. The knowledge of these mechanisms has a high value and relevant implications for many research fields both within and outside the neurosciences. The project aims to study the neurobehavioral correlates of verbal and non-verbal communication. Through the use of non-invasive behavioral and neurophysiological techniques, the study intends to highlight the neurobehavioral markers that allow to quantify the temporal evolution of communication dynamics in healthy subjects.",[98,99],"Neuroscience","Neuromodulation","2026-03-26",{"date":102,"type":39},"2026-03-31",{"date":104,"type":39},"2023-08-16",{"date":106,"type":20},"2026-08-16",{"name":45,"class":46},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":60,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":47},"100626319","impact-of-c-mill-rehabilitation-on-the-gut-brain-axis-in-parkinsons-disease-100626319","NCT07434089","Impact of C-Mill Rehabilitation on the Gut-Brain Axis in Parkinson's Disease","Gut-Brain Axis and Rehabilitation: Study on the Effects of C-Mill Technology on the Intestinal Microbiota of Parkinson's Disease Patients","Inclusion Criteria:\n\n* Diagnosis of PD according to the Movement Disorder Society Clinical\n* Diagnostic Criteria for Parkinson's Disease\n* Age comprised between 40 to 70 years\n* Patients with moderate to advanced disease (2 ≤ Hoehn and Yahr classification grade ≤ 4)\n* Individuals able to walk independently (FAC \\> 2)\n\nExclusion Criteria:\n\n* PD patients with (1) weight \\> 135 kg and Height \\> 200 cm\n* Open lesions or bandages whether in contact with the harness of C-Mill strumentation\n* chronic gastro-intestinal (GI) disease including malabsorption;\n* clinical history of gastric lesions, gastro-resection or major intestinal surgery;\n* systemic and\u002For neurologic infectious, inflammatory, or autoimmune diseases of gastro-intestinal (GI) eg. Chron disease;\n* Acute GI phlogosis or GI disease in the last 4 weeks before recruitment;\n* Use of domperidone, or any drug potentially affecting gastrointestinal motility and integrity;\n* Use, in the last 4 weeks preceding the recruitment and until t2, of pre-probiotics or therapy based upon steroids, nonsteroidal anti-inflammatory drugs, antibiotics or antifungals;\n* anamnesis suggestive of GI cancer pathology.","70 Years",{"count":117,"type":20},60,[62],"The GM-REHAB-2025 study aims to evaluate the impact of physiotherapy interventions using the C-Mill treadmill, with and without semi-immersive virtual reality, on gut microbiota and metabolic parameters in patients with Parkinson's disease. Three groups will be involved: one undergoing conventional physiotherapy, one treated with the C-Mill without virtual reality (VR), and one treated with C-Mill technology combined with VR. Clinical assessments and the collection of biological samples (stool, serum, and plasma) will be carried out at three time points: at baseline, at the end of treatment (21 days), and after 3 months.",[69],"2026-02-20",{"date":123,"type":39},"2026-02-25",{"date":125,"type":39},"2025-10-20",{"date":127,"type":20},"2028-10-20",{"name":45,"class":46},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":91,"sex":15,"minAge":136,"maxAge":16,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":47},"100625414","multidimensional-assessment-of-mental-health-in-adolescence-100625414","NCT07422324","Multidimensional Assessment of Mental Health in Adolescence.","Multidimensional Assessment of Mental Health in Adolescence: Cross-sectional Study Using Self-report and Parent-report Questionnaires.","Inclusion Criteria:\n\n* adolescents aged between 11 and 18;\n* consent from legal guardians\u002Fparents;\n* good reading and comprehension skills, absence of sensory impairments that prevent them from completing the questionnaires independently.\n\nExclusion Criteria:\n\n* age not between 11-18 years;\n* failure to obtain consent from legal guardians\u002Fparents;\n* overt difficulties in reading and understanding the text, presence of sensory deficits that prevent independent completion of the questionnaires.","11 Years",{"count":138,"type":20},180,"Evidence indicates that many mental disorders in adulthood originate during adolescence, with a typical onset between the ages of 14 and 18, especially for anxiety, mood, and behavioral disorders. Over the past 20 years, the prevalence of psychiatric disorders among children and adolescents has increased globally, influenced by factors such as environmental stress, digital technologies, socioeconomic inequalities, and the consequences of the COVID-19 pandemic. Approximately one in seven adolescents worldwide suffers from a diagnosable mental disorder, with a growing trend, especially in high-income countries.\n\nA multidimensional and multi-informant assessment, integrating the perspectives of adolescents and parents, is essential for the early detection of signs of psychological distress and the definition of targeted interventions.\n\nMain objective:\n\nTo assess the mental health of adolescents (aged 11-18) using multidimensional psychometric tools to identify early signs of distress and vulnerability.",[141],"Mental Disease","2026-02-16",{"date":121,"type":39},{"date":145,"type":39},"2025-10-27",{"date":147,"type":20},"2027-03-31",{"name":45,"class":46},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":15,"minAge":156,"maxAge":16,"enrollmentInfo":157,"targetDuration":4,"studyType":60,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100625719","virtual-reality-supported-rehabilitation-for-childrens-executive-and-metaphonological-skills-100625719","NCT07426289","Virtual Reality Supported Rehabilitation for Children's Executive and Metaphonological Skills","Evaluating the Effectiveness of a Virtual Reality Rehabilitation System (VRRS) Intervention on Executive Function Enhancement and Monitoring of Metaphonological Skills in ADHD Children","Inclusion Criteria:Inclusion Criteria:\n\n* Children aged 8 to 12 years\n* Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)\n* Attending 3rd, 4th, or 5th grade of primary school\n* IQ greater than 70 (based on recent cognitive assessment)\n* Presence of executive function impairment and\u002For metaphonological difficulties\n* Availability of a baseline neuropsychological assessment (T0) completed within the last 3 months\n* Parental consent obtained\n\nExclusion Criteria:\n\n* Comorbid diagnosis of specific learning disorders (SLD)\n* Neurological, genetic, or psychiatric comorbidities other than ADHD\n* Uncorrected sensory impairments (vision or hearing)\n* Lack of informed consent","6 Years",{"count":158,"type":20},50,[62],"Executive functions and metaphonological skills are closely interconnected in supporting language development and learning processes.Investigating this relationship could offer new insights into how executive and metaphonological skills interact, supporting the development of integrated intervention strategies targeting both cognitive and linguistic domains.\n\nThis study aims to evaluate the effectiveness of a rehabilitation intervention using a virtual reality system (VRRS) in enhancing executive functions and monitoring metaphonological skills in children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD).The aim is to explore whether a semi-immersive digital cognitive training protocol can lead to measurable improvements in executive functions, and whether such improvements are associated with gains in metaphonological skills.\n\nParticipants will present deficits in executive functions and metaphonological skills and will undergo pre- and post-intervention assessments. These assessments include standardized neuropsychological and speech-language pathology tools designed to detect impairments in attention, inhibition, working memory, phonological awareness, and behavior in home and school settings.",[162],"Attention Deficit Hyperactivity Disorder (ADHD)","NOT_YET_RECRUITING",{"date":165,"type":39},"2026-02-23",{"date":102,"type":20},{"date":168,"type":20},"2030-12-31",{"name":45,"class":46},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":15,"minAge":177,"maxAge":16,"enrollmentInfo":178,"targetDuration":4,"studyType":60,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":47},"100625721","innovative-methodologies-for-neuroplasticity-in-developmental-age-with-the-use-of-virtual-reality-100625721","NCT07426315","Innovative Methodologies for Neuroplasticity in Developmental Age With the Use of Virtual Reality","M.I.N.E.R.V.A., Metodologie Innovative Per la Neuroplasticità in Età Evolutiva Con l'Uso Della Realtà Virtuale a Scopo Abilitativo","Inclusion Criteria:\n\n* Children and adolescents aged 8 to 18 years\n* Diagnosis of one of the following neurodevelopmental disorders:\n\n  * Attention Deficit Hyperactivity Disorder (ADHD)\n  * Autism Spectrum Disorder (ASD)\n  * Cerebral Palsy (CP)\n* Ability to understand and comply with instructions for the intervention\n* Adequate cognitive, motor, and social skills to participate in the rehabilitation program\n* Informed consent obtained from a parent or legal guardian\n\nExclusion Criteria:\n\n* Children and adolescents younger than 8 or older than 18 years\n* Severe cognitive impairments or intellectual disabilities that prevent participation in the rehabilitation program\n* Diagnosis of conditions not related to the target neurodevelopmental disorders, such as:\n\n  * Major psychiatric disorders (e.g., severe depression, schizophrenia)\n  * Neurological disorders not included in the study (e.g., epilepsy)\n* Severe motor impairments that prevent interaction with the virtual reality platform\n* Uncontrolled medical conditions (e.g., severe cardiovascular, respiratory, or endocrine diseases)\n* Lack of informed consent from a parent or legal guardian\n* Participation in another intervention or study that may interfere with the rehabilitation program\n* Behavioral issues or extreme anxiety that make it impossible to follow instructions or interact with the virtual reality system","8 Years",{"count":179,"type":20},108,[62],"Neurodevelopmental disorders, such as Cerebral Palsy (CP), Attention-Deficit\u002FHyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), are complex conditions that affect various aspects of children's development. Despite advancements in treatments, conventional rehabilitative interventions tend to focus on specific aspects, often overlooking the holistic needs of the patient. Many of these interventions fail to engage children, who may feel uninvolved or demotivated. Innovative technologies, such as immersive virtual reality (IVR), offer a promising alternative to make rehabilitation more engaging and comprehensive. This study aims to evaluate the effects of IVR-based rehabilitation on children and adolescents with neurodevelopmental disorders, focusing on improvements in cognitive, motor, and social functions. We hypothesize that IVR will enhance social interaction, attention, motor skills, and overall quality of life. The study will include children and adolescents aged 8 to 18 years, diagnosed with ADHD, ASD, and cerebral palsy. The CAR-EN platform, which provides a highly customizable therapeutic environment, will be used. Assessments will measure cognitive, motor, and social skills before and after the intervention. We expect immersive virtual reality to lead to significant improvements in the participants' cognitive, motor, and social abilities. These findings could potentially contribute to a shift in therapeutic guidelines, offering more effective treatments for children with neurodevelopmental disorders.",[183],"Neurodevelopmental Disorders",{"date":165,"type":39},{"date":186,"type":39},"2025-08-14",{"date":188,"type":20},"2028-08",{"name":45,"class":46},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":60,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":47},"100622478","cognitive-recovery-via-sensor-based-robotic-upper-limb-rehabilitation-in-neurological-disorders-100622478","NCT07384143","Cognitive Recovery Via Sensor-based Robotic Upper Limb Rehabilitation in Neurological Disorders","Exploring Cognitive Recovery: the Impact of Sensor-based Robotic Rehabilitation in Neurological and Neurodegenerative Disorders","CROSS-ND","Inclusion Criteria:\n\n* Age 18-75 years;\n* FMA-UL 0-31: eligible for exoskeletons and robotic devices with high support. (Armeo Power, Amadeo, Motore)\n* FMA-UL 32-47: eligible for end-effectors with medium support. (Armeo Spring, Hand Tutor, Diego)\n* FMA-UL 48-52: eligible for sensor-based with low support. (Pablo, Diego, Armeo Senso)\n* MoCA: ≤ 20\n\nExclusion Criteria:\n\n* Severe cognitive disorders\n* Behavioral disorders\n* Sensory disorders","75 Years",{"count":200,"type":20},189,[62],"The goal of this clinical trial is to learn if sensor-based robotic upper limb rehabilitation can improve cognitive and motor functions in adults with neurological and neurodegenerative disorders, including Parkinson's disease, multiple sclerosis, and stroke. The main questions it aims to answer are:\n\nDoes sensor-based robotic rehabilitation improve cognitive functions such as attention, memory, and executive functions? Does this rehabilitation lead to better motor recovery and daily functioning compared to conventional therapy? Researchers will compare the experimental group receiving robotic rehabilitation with cognitive tasks to the control group receiving conventional therapy to see if the robotic approach leads to greater improvements in both cognitive and motor outcomes.\n\nParticipants will:\n\nReceive upper limb rehabilitation using robotic devices and virtual reality-based exercises or conventional therapy Complete a series of neuropsychological assessments before and after the intervention to measure cognitive changes Complete motor function tests before and after the intervention to evaluate physical improvements Participate in 25 training sessions, 2-3 times per week, each lasting 60 minutes",[204,205,206,207],"PARKINSON DISEASE (Disorder)","Multiple Sclerosis","Stroke","Neurological Disorders","2026-01-26",{"date":210,"type":39},"2026-02-03",{"date":212,"type":39},"2025-02-11",{"date":214,"type":20},"2030-02-11",{"name":45,"class":46},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":15,"minAge":224,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":47},"100620541","mild-cognitive-impairment-and-psychopathology-100620541","NCT07358962","Mild Cognitive Impairment and Psychopathology","Mild Cognitive Impairment and Psychopathology: Effects on Awareness, Social Life, and Work. Cross-sectional Observational Study","MIND","Inclusion Criteria:\n\n* Age between 50 and 72 years;\n* Diagnosis of Mild Cognitive Impairment (MCI), with referral to the Neuropsychology clinic for an initial evaluation or for clinical monitoring;\n* Absence of behavioral, psychiatric, or sensory disorders that could significantly compromise the performance of cognitive tests or the completion of questionnaires.\n\nExclusion Criteria:\n\n* Neurological disorders other than MCI, such as recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, or other atypical neurodegenerative diseases;\n* Major psychiatric comorbidities not stabilized at the time of the assessment (e.g., schizophrenia, bipolar disorder in an active phase, untreated severe depression);\n* Severe uncorrected sensory deficits (visual or hearing) capable of compromising the validity of cognitive and functional assessments;\n* Use of medications with significant potential cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of the assessment;\n* Terminal-stage internal or oncological diseases, or other medical conditions that significantly interfere with the assessment procedures.","50 Years","72 Years",{"count":227,"type":20},118,"Mild Cognitive Impairment (MCI) is a condition characterized by cognitive deterioration greater than what is expected from normal aging, representing an important risk factor for the development of dementia. Early assessment of cognitive functions is therefore essential for promptly identifying any signs of decline. In addition to cognitive aspects, it is equally important to consider the possible psychopathological profile of patients, as such disorders can significantly influence the progression of the disease, quality of life, and the ability to manage daily activities. This protocol aims to explore the presence of psychopathological disorders in patients with MCI, with particular attention to their impact on awareness of cognitive deficits (anosognosia) and on the subjective perception of difficulties in daily life, especially in social and work contexts. The study seeks to outline a comprehensive picture of the psychopathological profile in patients with MCI, facilitating the identification of targeted and personalized interventions capable of improving clinical management and the overall well-being of the individual.",[73],[73,231,232,233,234,235,236],"Psychopathological disorders","Anosognosia","Cognitive decline","Social functioning","Work functioning","Neuropsychological assessment","2026-01-14",{"date":239,"type":39},"2026-01-22",{"date":241,"type":20},"2026-01-12",{"date":243,"type":20},"2027-01-12",{"name":45,"class":46},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":15,"minAge":253,"maxAge":198,"enrollmentInfo":254,"targetDuration":4,"studyType":60,"phases":256,"briefSummary":257,"conditions":258,"keywords":261,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":47},"100620696","myrosinase-bioactivated-gglucoraphanin-for-the-treatment-of-neurodegenerative-diseases-gra-myr-nd-100620696","NCT07360977","Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)","A Composition Comprising Glucoraphanin, Myrosinase and a Buffered Solution for Use in the Treatment of Neurodegenerative Diseases","GRA-MYR-ND","Inclusion Criteria:\n\nInclusion Criteria for PD:\n\n* Male or female patients aged between 45-75 years old.\n* Clinical diagnosis of PD according to UK Brain Bank Criteria.\n* 3 months of clinical stability before study enrolment.\n* Anti-parkinsonian medication is fixed for at least 3 months prior to study entry.\n\nInclusion Criteria for MS:\n\n* Male or female patients 18 years old or older.\n* Diagnosis of RR-MS according to McDonald criteria.\n* Expanded Disability Status Scale(EDSS) lower or equal to 5.5.\n* Stable disease for at least 30 days prior to study entry.\n* Stable disease-modifying therapy for at least 3 months prior to study entry.\n\nCommon inclusion criteria for MS and PD:\n\n* No changes in drug treatment during 6 months-study treatment.\n* Patients understand and comply with the study procedure and are able to complete tests and examinations required by the project.\n* Written informed consent.\n\nInclusion criteria for pediatric patients:\n\n* Eligible patients are those clinically stable;\n* Age range from 1 to 10, between 5 and 30 kg.\n* Patients not involved in other clinical trials.\n\nExclusion Criteria:\n\nExclusion criteria for PD and MS:\n\n* Absolute contraindications to Magnetic Resonance Imaging (MRI).\n* Concomitant neurological disease or severe co-morbidities able to influence outcomes such as spinal injury, cancer, dementia, or other central nervous system diseases such as stroke, epilepsy or psychiatric disorders;\n* Total score of Mini-Mental State Examination (MMSE)\\\u003C24.\n* Participating in other clinical trials.\n* Pregnant\u002Flactating.","1 Year",{"count":255,"type":20},300,[62],"Glucosinolates (GLs) are phytocompounds mainly found in the Cruciferae (Brassicacea) and Moringa oleifera plants. The hydrolysis of GLs by myrosinase led to the production of isothiocyanate (ITCs). ITCs consumption was associated with different health promoting effects, including to neuroprotective, anti-oxidant and anti-inflammatory capacities. In particular, they showed neuroprotective effects in experimental models of neurodegenerative diseases, including multiple sclerosis (MS) and Parkinson's disease (PD). From different GLs, different ITCs are originated. In particular, from glucoraphanin (GRA) the ITC sulforaphane (SFN) is obtained. The PI of the project is one of the proprietor of a patent (EP2908850B1) for the application of (Rs)-GRA with myrosinase in a buffered solution for the treatment of neurodegenerative diseases. The aim of this project is to evaluate the effects of the administration of bioactivated GRA in different cohorts of adult patients, affected by MS and PD, but also a cohort of pediatric patients affected by neuromuscolar and degenerative diseases. The effects of bioactivated (Rs)-GRA administration will be evaluated with a combination of clinical evaluations and a multiomic (metabolomic, genomic) approach.",[204,259,260],"Multiple Sclerosis (MS) - Relapsing-remitting","Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases",[262,263,264,265,266],"phytocompounds","Glucosinolates","isothiocyanate","Parkinson's disease","multiple sclerosis",{"date":239,"type":39},{"date":269,"type":20},"2026-01",{"date":271,"type":20},"2026-05-19",{"name":45,"class":46},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":284,"conditions":285,"keywords":288,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":47},"100613605","personological-structure-cognitive-functions-and-central-sensitization-in-headache-100613605","NCT07268768","PERSONOLOGICAL STRUCTURE, COGNITIVE FUNCTIONS AND CENTRAL SENSITIZATION IN HEADACHE","Personological Structure, Cognitive Functions and Central Sensitization in Headache: Obstacles and Resources in the Treatment of Chronic and Episodic Headache.","AURA","Inclusion Criteria:\n\n* Age between 18 and 60 years;\n* Diagnosis of chronic or episodic headache;\n* Patients attending the Headache Outpatient Clinic.\n\nExclusion Criteria:\n\n* Presence of severe psychiatric and neurological disorders;\n* Presence of oncological diseases in terminal stage","60 Years",{"count":283,"type":20},64,"Headache, in its episodic and chronic forms, cannot be considered solely as an isolated neurological symptom, but as a complex condition of a bio-psycho-social nature. While in the episodic form the painful episodes occur intermittently and have a variable impact on daily life, in the chronic form the disease evolves towards persistent pain, with more significant consequences on personal, social and work functioning. The following study protocol aims to investigate in an integrated manner the neurological, cognitive and psychological mechanisms involved in headache, with particular attention to the differences between episodic and chronic forms. The main objective is to assess the neuropsychological profiles and pain response of patients, monitoring their evolution over a period of approximately six months, considering the impact of central sensitisation, personality structure and any psychopathological comorbidities on pain management and treatment adherence. The protocol adopts a multidimensional approach aimed at optimising therapeutic efficacy and improving patients' quality of life, preventing progression to chronicity.",[286,287],"Chronic and Episodic Headache","Headache Disorders",[289],"chronic migraine; central sensitization; cognitive impairment; personality disorders; treatment adherence; anxiety; depression;","2025-12-05",{"date":292,"type":39},"2025-12-08",{"date":294,"type":39},"2025-11-20",{"date":296,"type":20},"2028-11-20",{"name":45,"class":46},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":15,"minAge":224,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":47},"100615039","dementia-and-mild-cognitive-impairment-assessment-of-cognitive-functioning-functional-autonomy-and-neuropsychiatric-symptoms-100615039","NCT07287410","Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.","RE-MIDA","Inclusion Criteria:\n\n* Age between 50 and 86 years.\n* Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI).\n* Referral to the neuropsychology clinic for initial assessment or clinical monitoring.\n* Absence of behavioral, psychiatric, or sensory disorders severe enough to significantly impair cognitive testing or completion of questionnaires.\n\nExclusion Criteria:\n\n* Presence of neurological disorders other than dementia or MCI (e.g., recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, atypical neurodegenerative diseases).\n* Unstable major psychiatric comorbidities at the time of assessment (e.g., schizophrenia, bipolar disorder in active phase, untreated severe depression).\n* Uncorrected severe sensory deficits (visual or auditory) affecting the validity of cognitive or functional assessments.\n* Use of medications with significant cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of evaluation.\n* Presence of terminal medical or oncological conditions or other illnesses significantly interfering with the assessment procedures.","86 Years",{"count":307,"type":20},151,"Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.",[310,73],"Dementia",[310,67,312,313,314],"neuropsychological","Activities of Daily Living","Neuropsychiatric symptoms","2025-12-03",{"date":317,"type":39},"2025-12-17",{"date":319,"type":20},"2025-12",{"date":321,"type":20},"2026-12-20",{"name":45,"class":46},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":198,"enrollmentInfo":331,"targetDuration":4,"studyType":60,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":47},"100534259","effect-of-transcranial-direct-current-stimulation-in-altered-states-of-consciousness-100534259","NCT06236503","Effect of Transcranial Direct Current Stimulation in Altered States of Consciousness","Effect of Daily Transcranial Direct Current Stimulation on the Cognitive Evolution of Patients in an Altered State of Consciousness","tDCS-GCA","Inclusion Criteria:\n\n* Patients diagnosed with a minimally conscious state will be evaluated and stimulated, provided that written informed consent is obtained from a family member.\n\nExclusion Criteria:\n\npatients in coma patients with metallic brain implants, craniotomy or pacemaker",{"count":332,"type":20},100,[62],"Transcranial Direct Current Stimulation (tDCS) is a non-invasive, painless brain stimulation treatment that uses low-intensity direct electrical currents to stimulate specific parts of the brain. Transcranial Direct Current Stimulation (tDCS) can both facilitate anodic stimulation and inhibit cathodic stimulation specific brain areas since many neurological and psychiatric disorders are connected to hypoactivity or hyperactivity in specific areas of the nervous system. This phenomenon is based on two processes: the reorganization of functional neural circuits and their reconstruction. In light of the studies mentioned above, it is presumed that Transcranial Direct Current Stimulation (tDCS) can be a valuable tool to facilitate the process of neuroplasticity in individuals with chronic neurological diseases and in patients with impaired consciousness following severe brain injury. A previous study demonstrated that a single session of transcranial direct current electrical stimulation could temporarily improve signs of consciousness in patients in a minimally conscious state (MCS)",[336,337],"Neurologic Disorder","Brain Injuries","2025-04-29",{"date":340,"type":39},"2025-05-01",{"date":342,"type":39},"2023-01-10",{"date":344,"type":20},"2025-12-30",{"name":45,"class":46},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":281,"enrollmentInfo":354,"targetDuration":4,"studyType":60,"phases":355,"briefSummary":356,"conditions":357,"keywords":361,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":47},"100582124","new-technological-pathway-for-gait-rehabilitation-100582124","NCT06859229","New Technological Pathway for Gait Rehabilitation","Effects on Gait Patterns of a New Technological Pathway for Gait Rehabilitation in Patients With Movement Disorders","LABODIMOTO","Inclusion Criteria:\n\n* Patients with a Montreal Cognitive Assessment (MoCA) score, corrected for age and education, equal to or greater than 20.\n* Subjects capable of walking independently (Functional Ambulation Categories - FAC \\> 2).\n\nExclusion Criteria:\n\n* Cognitive impairments that compromise the understanding and\u002For execution of the proposed exercises.\n* Associated comorbidities that prevent maintaining an upright position or walking (e.g., hypotension).\n* Refusal or inability to provide informed consent.\n* Patients with contraindications to the use of the technological equipment required for the dynamic movement pathway.",{"count":117,"type":20},[62],"\\*\\*Brief Summary\\*\\*\n\nThe study aims to explore how the integration of visual and motor systems can be trained and enhanced to improve gait rehabilitation in patients with various neurological and cardiovascular conditions. Scientific evidence highlights that physical activity requires coordination and precise processing of visual, auditory, and sensory information from the external environment, which is then integrated at the brain level. This process establishes synaptic connections that direct the movement of arms, hands, legs, and the trunk through bottom-up and top-down mechanisms. However, inaccurate or incomplete perceptual information can impair performance, even when accurate visual stimuli are provided, emphasizing the importance of assessing and enhancing visuo-motor integration.\n\nThe research investigates the central mechanisms controlling peripheral muscle activation patterns during gait. While over-ground walking in healthy individuals generally does not activate the prefrontal cortex except in dual-task scenarios, evidence suggests that post-stroke patients exhibit increased prefrontal cortex metabolism during walking. Recent studies have shown that gait training with exoskeletal systems improves walking patterns in post-stroke patients by altering muscle activation patterns and increasing fronto-parietal connectivity.\n\nThis study seeks to answer the following question: How do central and peripheral mechanisms interact to influence gait rehabilitation outcomes, and what role do visuo-motor integration and neuroplasticity play in this process? To address this, advanced neuroimaging technologies such as fMRI, dtMRI, and NIRS will be employed to investigate these mechanisms in vivo.",[358,359,360],"Neurological Diseases or Conditions","Cardiovascular Diseases","Neuromuscular Disease",[362,363,364,365],"neurorehabilitation","gait rehabilitation","analysis of movement","neuroplasticity","2025-03-04",{"date":368,"type":39},"2025-03-05",{"date":370,"type":20},"2025-03",{"date":372,"type":20},"2027-02",{"name":45,"class":46},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":15,"minAge":381,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":60,"phases":385,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":47},"100501378","eye-tracking-technology-for-severe-communication-disability-100501378","NCT05808478","Eye-tracking Technology for Severe Communication Disability","Augmentative Alternative Communication Intervention Delivered Via Eye-tracking Technology","Inclusion Criteria:\n\n* aged between 3 and 17 years affected by neuropsychiatric pathology presenting complex communication needs\n* Control of eye motility and visual fixation\n* ability to maintain position in front of the monitor\n* availability of at least one member of the family nucleus to participate in the therapeutic process\n* cognitive skills appropriate to the task such as being able to recognize images and being able to memorize procedures necessary to use the various basic functions\n\nExclusion Criteria:\n\n* age not between 3 and 17 years\n* difficulty in controlling ocular motility and visual fixation\n* the unavailability of at least one member of the family nucleus to participate in the therapeutic process\n* impaired cognitive skills on the task such as being able to recognize pictures and being able to memorize procedures necessary to use various basic functions","3 Years","17 Years",{"count":384,"type":20},30,[62],"The aim of this project is to develop an Augmentative and Alternative Communication intervention through the use of Eye tracker system.",[388],"Communication Disabilities",[390],"Augmentative and Alternative Communication, Eye tracker, Communication Disabilities","2023-03-30",{"date":393,"type":39},"2023-04-11",{"date":395,"type":39},"2022-01-22",{"date":82,"type":20},{"name":45,"class":46},""]